Details of the Drug Combination

General Information of Drug Combination (ID: DCAK45W)

Drug Combination Name
JNK-IN-8 TEM
Indication
Disease Entry Status REF
Colon carcinoma Investigative [1]
Component Drugs JNK-IN-8   DMLWYJB TEM   DMLNFWU
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL
High-throughput Screening Result Testing Cell Line: KM12
Zero Interaction Potency (ZIP) Score: 3.14
Bliss Independence Score: 6.31
Loewe Additivity Score: 1.72
LHighest Single Agent (HSA) Score: 11.56

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of JNK-IN-8
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [2]
JNK-IN-8 Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Stress-activated protein kinase JNK3 (JNK3) TT056SO MK10_HUMAN Inhibitor [2]
JNK2 messenger RNA (JNK2 mRNA) TT3IVG2 MK09_HUMAN Inhibitor [2]
Stress-activated protein kinase JNK1 (JNK1) TT0K6EO MK08_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
JNK-IN-8 Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cell division cycle and apoptosis regulator protein 1 (CCAR1) OTUXLQZZ CCAR1_HUMAN Increases Expression [4]
------------------------------------------------------------------------------------
Indication(s) of TEM
Disease Entry ICD 11 Status REF
Postherpetic neuralgia 1E91.5 Phase 2 [3]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCF5G66 SW-620 Investigative [5]
Minimally invasive lung adenocarcinoma DC4RIDX NCI-H322M Investigative [5]
------------------------------------------------------------------------------------

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030055)
4 A H2AX?CARP-1 Interaction Regulates Apoptosis Signaling Following DNA Damage. Cancers (Basel). 2019 Feb 14;11(2):221. doi: 10.3390/cancers11020221.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.